UK recommends limiting Astrazeneca in under-30s
EU, UK emphasise vaccine benefits outweigh clot risks
British authorities recommended yesterday that the Astrazeneca Covid-19 vaccine not be given to adults under 30 where possible because of strengthening evidence that the shot may be linked to rare blood clots.
The recommendation came as regulators in the United Kingdom and the European Union emphasised that the benefits of receiving the vaccine continue to outweigh the risks for most people — even though the European Medicines Agency said it had found a “possible link” between the shot and the rare clots. British authorities recommended that people under 30 be offered alternatives to Astrazeneca. But the EMA advised no such age restrictions, leaving it up to its member-countries to decide whether to limit its use.
Several countries have already imposed limits on who can receive the vaccine, and any restrictions are closely watched since the vaccine, which is cheaper and easier to store than many others, is critical to global immunisation campaigns and is a pillar of the Unbacked programme known as Covax that aims to get vaccines to some of the world’s poorest countries.
“This is a course correction, there’s no question about that,” Jonathan Van-tam, England’s deputy chief medical officer, said during a news briefing.
Van-tam said the effect on Britain’s vaccination timetable — one of the speediest in the world — should be “zero or negligible”, assuming the National Health Service receives expected deliveries of other vaccines, including those produced by Pfizerbiontech and Moderna.
EU and UK regulators held simultaneous news conferences yesterday to announce the results of investigations into reports of blood clots that sparked concern about the rollout of the Astrazeneca vaccine.
The EU agency described the clots as “very rare” side effects. Dr Sabine Straus, chairwoman of its Safety Committee, said the best data was from Germany, where there was one report of the clots for every 100,000 doses given, although she noted far fewer reports in the UK.
That’s less than the clot risk that healthy women face from birth control pills, noted another expert, Dr Peter Arlett.
The agency said that most of the cases reported were in women under 60 within two weeks of vaccination, though it was unable to identify specific risk factors based on current information. Experts reviewed several dozen cases that came mainly from Europe and the UK, where about 25 million people have received the Astrazeneca vaccine.
In a statement, Astrazeneca said both UK and EU regulators had requested their vaccine labels be updated to warn of these “extremely rare potential side effect[s].”
“Both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks,” it said.
The EMA’S investigation focused on unusual types of blood clots that have occurred along with low blood platelets. One rare clot type appears in multiple blood vessels and the other in veins that drain blood from the brain.
“We are not advising a stop to any vaccination for any individual in any age group,” said Wei Shen Lim, who chairs Britain’s Joint Committee on Vaccination and Immunisation. “We are advising a preference for one vaccine over another vaccine for a particular age group . . . out of the utmost caution rather than because we have any serious safety concerns.”
After the EMA announcement yesterday, officials in Spain said Astrazeneca would be limited to people over 60 years of age, and Italy issued a similar recommendation.
Belgium’s Health Minister, Frank Vandenbroucke, declared a fourweek ban on administering the Astrazeneca vaccine to people under 56. —AP